The efficacy and safety of tislelizumab combined with weekly nab-paclitaxel, carboplatin, and cetuximab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a real-world study.

Front Immunol · 2025 · PMC12827551 · PMID 41583496

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

a trend toward significanceP < 0.1so close (0.05 < p ≤ 0.1)

First, univariate Cox regression identified three variables with a trend toward significance for PFS (P < 0.1): BMI, HALP, and SII; and three variables for OS (P < 0.05): location, HALP, and post-treatment SII changes.

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.